Investor relations

Research Report on BioGaia 20 August 2009

Danske Markets Equities has published a research report on BioGaia. Danske Markets Equities is the unit in Danske Bank responsible for Nordic Equity Sales, Trading and Research. Below is a direct quotation of the synopsis of the report:
"BioGaia delivers improved health through products that contain a patented bacteria, Lactobacillus reuteri, with clinically proven effects. With sales increasing fourfold in the past five years, and with a stable cost base now covered, we forecast almost exponential margin expansion in coming years. We initiate coverage with a Buy rating and a 12-month target price of SEK100 per share, indicating an upside potential exceeding 50%."

Institutional clients with a business relation to Danske Bank can find the full report at Danske Markets Equities.

Financial hearing hold by Peter Rothschild, VD. Link to the video and a slideshow in swedish, Presentation December 10, 2008

This presentation concerns BioGaia background, strategic milestones and markets. It also describes our products, delivery systems and strong partner support, and economic history and future.View BioGaia company presentation from 2008.
Company presentation 2008

Interim report 2009
Interim report q4
Interim report q3
Interim report q2
Interim report q1

Annual report 2008
Annual report 2008
The figures 2008
 

Plan for BioGaias Reports and Annual General Meeting 2010

February 22, 2010
Year-end report 2009

May 6, 2010
Interim report q1 2010

May 6, 2010
AGM 4:00 p.m in Stockholm
Shareholders who wish to have a matter dealt with at the AGM must notify the Board Chairman no later than 1 March 2010 by letter to BioGaia AB, Box 3242, SE-103 64 Stockholm, Sweden, or by e-mail to mr@biogaia.se

August 2010
Interim report q2 2010

October, 2010
Interim report q3 2010